natgillin/translations-raw huggingface dataset:
• Protelos/Osseor should only be used to treat severe osteoporosis in postmenopausal women and men at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance;
• Zdravilo Protelos/Osseor se lahko uporablja samo za zdravljenje hude osteoporoze pri ženskah po menopavzi in moških z velikim tveganjem za zlome, pri katerih zdravljenje z drugimi zdravili, odobrenimi za zdravljenje osteoporoze, ni mogoče, na primer zaradi kontraindikacij ali intolerance.
• Protelos/Osseor will only be prescribed for preventing fractures in post-menopausal women and men with severe osteoporosis who have a high risk of fracture and cannot be treated with other medicines approved for osteoporosis.
• Zdravilo Protelos/Osseor se bo predpisovalo samo za preprečevanje zlomov pri ženskah po menopavzi in moških s hudo osteoporozo, pri katerih obstaja veliko tveganje za zlome in jih ni mogoče zdraviti z drugimi zdravili, ki so odobrena za osteoporozo.
The CHMP considered that the cardiovascular risk in patients taking Protelos/Osseor can be managed by restricting its use to patients with no history of heart and circulatory problems and limiting its use to those who cannot take other medicines approved for the treatment of osteoporosis.
Odbor CHMP je menil, da je srčno-žilno tveganje pri bolnikih, ki uporabljajo zdravilo Protelos/Osseor, mogoče obvladati tako, da se uporaba zdravila omeji na bolnike, ki v anamnezi nimajo bolezni srca in ožilja, ter dodatno na tiste, ki ne morejo uporabljati drugih zdravil, ki so odobrena za zdravljenje osteoporoze.
Available data do not show evidence of an increased cardiovascular risk in patients without established, current or past history of ischaemic heart disease, peripheral arterial disease or cerebrovascular disease, or in those without uncontrolled hypertension.
Razpoložljivi podatki ne kažejo povečanega srčno-žilnega tveganja pri bolnikih brez ugotovljene obstoječe ali pretekle ishemične bolezni srca, periferne arterijske bolezni in/ali možgansko-žilne bolezni ter pri bolnikih z nenadzorovano hipertenzijo.
• Protelos/Osseor must not be used in patients with established, current or past history of ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease, or those with uncontrolled hypertension;
• Zdravilo Protelos/Osseor se ne sme uporabljati pri bolnikih z ugotovljeno obstoječo ali preteklo ishemično boleznijo srca, periferno arterijsko boleznijo in/ali možgansko-žilno boleznijo ter pri bolnikih z nenadzorovano hipertenzijo.
As recommended in a previous review, patients who have a history of certain heart or circulatory problems, such as stroke and heart attack, must not use the medicine.
V skladu s priporočili iz predhodnega pregleda zdravila ne smejo uporabljati bolniki, ki imajo v anamnezi določene bolezni srca ali ožilja, kot sta možganska in srčna kap.
• Protelos/Osseor should be stopped if the patient develops ischaemic heart disease, peripheral arterial disease or cerebrovascular disease, or if hypertension is uncontrolled;
• Zdravljenje z zdravilom Protelos/Osseor je treba prekiniti, če se pri bolniku pojavi ishemična bolezen srca, periferna arterijska bolezen ali možgansko-žilna bolezen, ter v primeru nenadzorovane hipertenzije.
The Committee concluded that given the benefits seen in preventing fractures in patients at high risk, Protelos/Osseor
Odbor je ob upoštevanju koristi, ki so jih opazili pri preprečevanju zlomov pri bolnikih z
• Your treatment with Protelos/Osseor will be stopped if you develop heart or circulatory problems during treatment.
• Če se bodo med zdravljenjem z zdravilom Protelos/Osseor pri vas pojavile težave s srcem ali ožiljem, bo zdravnik zdravljenje prekinil.
There was also an unvaccinated control group.
V študijo je bila vključena tudi necepljena kontrolna skupina.
The European Commission granted a marketing authorisation valid throughout the European Union, for Eryseng Parvo on 8 July 2014.
Evropska komisija je dovoljenje za promet z zdravilom Eryseng Parvo, veljavno po vsej Evropski uniji, izdala 8. julija 2014.
For swine erysipelas two laboratory studies were conducted.
Za svinjsko rdečico sta bili izvedeni dve laboratorijski študiji.
The most common side effect (seen in more than 1 in 10 pigs) with Eryseng Parvo is mild to moderate inflammation at the injection site which typically resolves within four days but in some cases may persist for up to 12 days post-vaccination.
Najpogostejši neželeni učinek (opažen pri več kot 1 prašiču od 10) zdravila Eryseng Parvo je blago do zmerno vnetje na mestu injiciranja, ki običajno izzveni v štirih dneh, v nekaterih primerih pa vztraja do 12 dni po cepljenju.
The parvovirus study showed that Eryseng Parvo protected 100% of the foetuses whilst 89% of foetuses were mummified in the control group.
Študija s parvovirusom je pokazala, da je zdravilo Eryseng Parvo zaščitilo 100 % fetusov, medtem ko je bilo v kontrolni skupini 89 % fetusov mumificiranih.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Eryseng Parvo exceed the risks for the approved indication and recommended that Eryseng Parvo be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Eryseng Parvo večje od z njim povezanih tveganj za odobreno indikacijo, in priporočil izdajo dovoljenja za promet z zdravilom Eryseng Parvo.
Other information about Eryseng Parvo:
Druge informacije o zdravilu Eryseng Parvo:
Eryseng Parvo is available as a suspension for injection.
Zdravilo Eryseng Parvo je na voljo v obliki suspenzije za injiciranje.
For porcine parvovirus a laboratory study was conducted involving three groups of 11 gilts (female pigs that have not yet had piglets) vaccinated with different concentrations of porcine parvovirus.
Za prašičjo parvovirozo je bila izvedena laboratorijska študija, ki je vključevala tri skupine po 11 mladic (prašičjih samic, ki še niso prasile), cepljenih z različnimi koncentracijami prašičjega parvovirusa.
The second laboratory study involved 15 gilts which were vaccinated according to the basic vaccination schedule with a booster dose six months later.
V drugo laboratorijsko študijo je bilo vključenih 15 mladic, ki so jih cepili v skladu z osnovnim razporedom cepljenja, šest mesecev pozneje pa so prejele še poživitveni odmerek.
The first study involved 40 pigs; 30 pigs were vaccinated with two doses, separated by three weeks, while a control group of 10 pigs received placebo (dummy treatment).
V prvi študiji, v katero je bilo vključenih 40 prašičev, je bilo 30 prašičev cepljenih z dvema odmerkoma v presledku treh tednov, kontrolna skupina 10 prašičev pa je prejela placebo (zdravilo brez zdravilne učinkovine).
In the future, if the animals are exposed to porcine parvovirus and Erysipelothrix rhusiopathiae bacteria, the immune system will be able to respond more quickly.
Ob morebitni ponovni izpostavitvi prašičjemu parvovirusu in bakteriji Erysipelothrix rhusiopathiae se bo imunski sistem lahko odzval hitreje.
Pigs were vaccinated with two doses at an interval of three weeks, with the second dose given three to four weeks before mating.
Cepljene so bile z dvema odmerkoma v presledku treh tednov, pri čemer so drugi odmerek prejele tri do štiri tedne pred parjenjem.
The measure of effectiveness was absence of porcine parvovirus and anti-porcine parvovirus antibodies in the foetuses.
Merilo učinkovitosti je bila odsotnost prašičjega parvovirusa in protitelesa proti prašičjemu parvovirusu v fetusih.
Eryseng Parvo contains an adjuvant (aluminium hydroxide, DEAE-dextran and ginseng) to enhance the immune response.
Zdravilo Eryseng Parvo vsebuje tudi adjuvans (aluminijev hidroksid, DEAE-dekstran in ženšen) za povečanje imunskega odziva.
Pigs were challenged with parvovirus at day 40 of pregnancy and then euthanized (humanely killed) at day 90 of pregnancy.
Samicam so 40. dan brejosti vbrizgali parvovirus, 90. dan brejosti pa so jih evtanazirali (ubili na human način).
Eryseng Parvo is a vaccine.
Zdravilo Eryseng Parvo je cepivo.
For swine erysipelas, the first laboratory study showed that 90% (27 out of 30) of vaccinated pigs were protected against Erysipelothrix rhusiopathiae serotype 1 remaining free of specific skin lesions whilst 93% (28 out of 30) of vaccinated pigs were protected against Erysipelothrix rhusiopathiae serotype 2 remaining free of specific skin lesions.
Pri svinjski rdečici je prva laboratorijska študija pokazala, da je bilo 90 % (27 od 30) cepljenih prašičev zaščitenih pred serotipom 1 bakterije Erysipelothrix rhusiopathiae, kar pomeni, da se pri njih niso pojavile specifične kožne lezije, pred serotipom 2 bakterije Erysipelothrix rhusiopathiae pa je bilo zaščitenih 93 % (28 od 30) cepljenih prašičev, kar prav tako pomeni, da se pri njih niso pojavile specifične kožne lezije.
When Eryseng Parvo is given to pigs the animals' immune system recognises the virus and bacteria as ‘foreign' and makes antibodies against them.
Ko prašiče cepimo z zdravilom Eryseng Parvo, njihov imunski sistem virus in bakterije prepozna kot „tujke“ in proti njim razvije protitelesa.
Porcine parvovirus causes infertility, still births and small litters in sows (female pigs that have had piglets).
Prašičji parvovirus povzroča neplodnost, mrtvorojenost in majhna legla pri svinjah (prašičjih samicah, ki so že prasile).
What benefit has Eryseng Parvo shown during the studies?
Kakšne koristi je zdravilo Eryseng Parvo izkazalo med študijami?
Eryseng Parvo is a veterinary vaccine that contains inactivated (killed) porcine parvovirus and Erysipelothrix rhusiopathiae bacteria.
Zdravilo Eryseng Parvo je cepivo za uporabo v veterinarski medicini, ki vsebuje inaktivirana (uničena) prašičji parvovirus in bakterijo Erysipelothrix rhusiopathiae.
It contains a strain of porcine parvovirus called NADL-2 and a strain of Erysipelothrix rhusiopathiae called R32E11.
Vsebuje sev prašičjega parvovirusa NADL-2 in sev bakterije Erysipelothrix rhusiopathiae R32E11.
This will help protect them against porcine parvovirus and swine erysipelas.
To bo pripomoglo k zaščiti prašičev pred prašičjo parvovirozo in svinjsko rdečico.
The second laboratory study showed 93% (14 out of 15) pigs were protected against challenge with Erysipelothrix rhusiopathiae serotypes 1 and 2.
Druga laboratorijska študija je pokazala, da je bilo 93 % (14 od 15) samic zaščitenih pred serotipoma 1 in 2 bakterije Erysipelothrix rhusiopathiae.
Eryseng Parvo is also used to protect male and female pigs against swine erysipelas caused by Erysipelothrix rhusiopathiae, serotype 1 and serotype 2.
Zdravilo Eryseng Parvo se uporablja tudi za zaščito prašičjih samcev in samic pred svinjsko rdečico, ki jo povzroča bakterija Erysipelothrix rhusiopathiae serotipa 1 in serotipa 2.
What is the risk associated with Eryseng Parvo?
Kakšna tveganja so povezana z zdravilom Eryseng Parvo?
Porcine parvovirosis and swine erysipelas vaccine (inactivated)
cepivo proti prašičji parvovirozi in svinjski rdečici (inaktivirano)
Eryseng Parvo is used to protect embryonic and foetal (unborn) piglets against porcine parvovirus infection via the placenta.
Zdravilo Eryseng Parvo se uporablja za zaščito prašičjih zarodkov in fetusov (nerojenih pujskov) pred okužbo s prašičjim parvovirusom prek posteljice.
Why has Eryseng Parvo been approved?
Zakaj je bilo zdravilo Eryseng Parvo odobreno?
The withdrawal period for Eryseng Parvo is zero days.
Karenca za zdravilo Eryseng Parvo je nič dni.
What is Eryseng Parvo used for?
Za kaj se zdravilo Eryseng Parvo uporablja?
How has Eryseng Parvo been studied?
Kako je bilo zdravilo Eryseng Parvo raziskano?
What is Eryseng Parvo?
Kaj je zdravilo Eryseng Parvo?
How does Eryseng Parvo work?
Kako zdravilo Eryseng Parvo deluje?
Velmetia is taken twice a day.
Zdravilo Velmetia se jemlje dvakrat na dan.
The European Commission granted a marketing authorisation valid throughout the EU for Velmetia on 16 July 2008.
Evropska komisija je dovoljenje za promet z zdravilom Velmetia, veljavno po vsej Evropski uniji, odobrila dne 16. julija 2008.
The full EPAR for Velmetia can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Velmetia je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Velmetia.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Velmetia.
Other information about Velmetia
Druge informacije o zdravilu Velmetia
It must also not be used in patients who consume excessive amounts of alcohol or who are alcoholic, or in women who are breast-feeding.
Prav tako se ne sme uporabljati pri bolnikih, ki prekomerno uživajo alkohol ali so alkoholiki, ali pri doječih ženskah.
For more information about treatment with Velmetia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Velmetia preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Velmetia sitagliptin / metformin hydrochloride
Velmetia sitagliptin/metforminijev klorid
The most common side effect with Velmetia (seen in between 1 and 10 patients in 100) is nausea (feeling sick).
Najpogostejši neželeni učinek zdravila Velmetia (opažen pri 1 do 10 bolnikih od 100) je navzeja (slabost).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Velmetia.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Velmetia, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
What benefit has Velmetia shown during the studies?
Kakšne koristi je zdravilo Velmetia izkazalo med študijami?
The CHMP decided that Velmetia's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Velmetia večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The results of three further studies were used to support the use of Velmetia.
V podporo uporabi zdravila Velmetia so bili uporabljeni rezultati treh nadaljnjih študij.
If Velmetia is taken with a sulphonylurea or insulin, the dose of the sulphonylurea or insulin may need to be lowered, to avoid hypoglycaemia (low blood sugar levels).
Če se zdravilo Velmetia jemlje skupaj s sulfonilsečnino ali insulinom, bo morda treba odmerek sulfonilsečnine ali insulina zmanjšati, da ne bi prišlo do hipoglikemije (nizke ravni sladkorja v krvi).
Velmetia must not be used in people who are hypersensitive (allergic) to sitagliptin, metformin or any of the other ingredients.
Zdravila Velmetia ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) sitagliptin, metformin ali katero koli drugo sestavino zdravila.
The company carried out additional studies to show that the active substances in Velmetia are absorbed by the body in the same way as the two medicines given separately.
Družba je opravila še nadaljnje študije, da bi dokazala, da telo zdravilni učinkovini zdravila Velmetia absorbira na enak način, kot če sta vzeti v obliki ločenih zdravil.
Velmetia is a medicine that contains two active substances, sitagliptin and metformin hydrochloride.
Velmetia je zdravilo, ki vsebuje dve zdravilni učinkovini, sitagliptin in metforminijev klorid.
Velmetia should be taken with food to avoid any stomach problems caused by metformin.
Zdravilo Velmetia je treba jemati sočasno s hrano, da se preprečijo želodčne težave, ki jih povzroča metformin.
What is the risk associated with Velmetia?
Kakšna tveganja so povezana z zdravilom Velmetia?
Velmetia is used in patients with type 2 diabetes to improve the control of blood glucose (sugar) levels.
Zdravilo Velmetia se uporablja za zdravljenje bolnikov s sladkorno boleznijo tipa 2 za izboljšanje nadzora nad ravnmi glukoze (sladkorja) v krvi.
For the full list of all side effects reported with Velmetia, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Velmetia, glejte navodilo za uporabo.
The first included 1,091 patients who were not satisfactorily controlled on diet and exercise alone and compared the effect of Velmetia with that of metformin or sitagliptin alone.
V prvo je bilo vključenih 1 091 bolnikov, pri katerih zadosten nadzor ni bil dosežen zgolj z dieto in telesno vadbo, v njej pa so primerjali učinke zdravila Velmetia z učinki metformina ali sitagliptina, uporabljenih kot samostojni zdravili.
In the first of the three further studies, Velmetia was more effective than metformin or sitagliptin alone.
V prvi od treh dodatnih študij je bilo zdravilo Velmetia učinkovitejše od metformina ali sitagliptina, uporabljenih kot samostojni zdravili.
Why has Velmetia been approved?
Zakaj je bilo zdravilo Velmetia odobreno?
The active substances in Velmetia, sitagliptin and metformin hydrochloride, each have a different mode of action.
Zdravilni učinkovini v zdravilu Velmetia, sitagliptin in metforminijev klorid, imata različna načina delovanja.
Velmetia was more effective than metformin alone.
Zdravilo Velmetia je bilo učinkovitejše od metformina, uporabljenega kot samostojno zdravilo.
The company presented the results of three studies of Januvia/Xelevia to support the use of Velmetia in patients who were not satisfactorily controlled on their existing metformin treatment.
Družba je v podporo uporabi zdravila Velmetia pri bolnikih, pri katerih obstoječe zdravljenje z metforminom bolezni ni zadostno za nadzor bolezni, predstavila rezultate treh študij z zdraviloma Januvia in Xelevia.
What is Velmetia used for?
Za kaj se zdravilo Velmetia uporablja ?
How does Velmetia work?
Kako zdravilo Velmetia deluje?
How has Velmetia been studied?
Kako je bilo zdravilo Velmetia raziskano?
How is Velmetia used?
Kako se zdravilo Velmetia uporablja?
What is Velmetia?
Kaj je zdravilo Velmetia?
Ref.: EMEA/264546/2009 EMEA/H/C/770
: EMEA/264546/2009 EMEA/H/C/770
The European Commission granted a marketing authorisation valid throughout the European Union for Avamys to Glaxo Group Ltd on 11 January 2008.
Evropska komisija je dovoljenje za promet z zdravilom Avamys, veljavno po vsej Evropski uniji, odobrila družbi Glaxo Group Ltd dne 11. januarja 2008.
To get the most benefit from the medicine, it should be used regularly and at the same time every day.
Največji učinek zdravila dosežemo, če zdravilo uporabljamo redno in vsak dan ob istem času.
Similar results were seen in children aged six years and above.
Podobni rezultati so bili ugotovljeni pri otrocih, starih šest let in več.
Avamys fluticasone furoate EPAR summary for the public
Avamys flutikazon furoat Povzetek EPAR za javnost
Other information about Avamys:
Druge informacije o zdravilu Avamys:
The effects of Avamys were first tested in experimental models before being studied in humans.
Učinki zdravila Avamys so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
However, it was not possible to determine if Avamys worked in children below the age of six years, because there were too few children below this age included the studies.
Ni pa bilo mogoče ugotoviti, ali je zdravilo Avamys delovalo tudi pri otrocih, starih manj kot šest let, ker je bilo v študije vključenih premalo otrok iz te starostne skupine.
This leads to a reduction the release of substances that are involved in the inflammation process, such as histamine, reducing the symptoms of allergy.
Posledica tega je zmanjšano sproščanje snovi, ki sodelujejo v vnetnem procesu, kot je histamin, kar privede do zmanjšanja simptomov alergije.
It usually starts to work from eight hours after the first spray, but it may take several days to get the maximum benefit.
Zdravilo običajno začne delovati po osmih urah po prvi uporabi, vendar pa se največji učinek lahko pokaže šele nekaj dni po začetku zdravljenja.
It works in a similar way to naturally occurring corticosteroid hormones, reducing the activity of the immune system by attaching to receptors in various types of immune cell.
Ta deluje na podoben način kot naravno prisotni kortikosteroidni hormoni, in sicer tako, da z vezavo na receptorje različnih imunskih celic zmanjšuje delovanje imunskega sistema.
The Committee recommended that Avamys be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Avamys odobri dovoljenje za promet.
The lowest effective dose that keeps symptoms controlled should be used.
Uporabiti je treba najmanjši odmerek, ki še nadzoruje simptome.
The most common side effect with Avamys (seen in more than 1 patient in 10) is epistaxis (nosebleeds).
Najpogostejši neželeni učinek zdravila Avamys (opažen pri več kot 1 bolniku izmed 10) je epistaksa (krvavitve iz nosu).
The active substance in Avamys, fluticasone furoate, is a corticosteroid.
Zdravilna učinkovina v zdravilu Avamys, flutikazon furoat, je kortikosteroid.
This is generally mild or moderate and tends to affect adults who have used Avamys for more than six weeks.
Te so ponavadi blage do zmerne in so pogostejše pri odraslih, ki so uporabljali zdravilo Avamys več kot šest tednov.
What benefit has Avamys shown during the studies?
Kakšne koristi je zdravilo Avamys izkazalo med študijami?
Avamys was compared with placebo (a dummy treatment) in six main studies involving almost 2,500 patients.
Zdravilo Avamys so primerjali s placebom (zdravilom brez zdravilne učinkovine) v šestih glavnih študijah, v katere je bilo vključenih skoraj 2 500 bolnikov.
Avamys should only be used for as long as the patient is exposed to the allergen, such as pollen, house dust mites or other animals.
Zdravilo Avamys se lahko uporablja samo, dokler je bolnik izpostavljen alergenom, kot so cvetni prah, hišne pršice in druge živali.
The recommended dose of Avamys for patients aged 12 years and over is two sprays in each nostril once a day.
Priporočeni odmerek zdravila Avamys pri bolnikih, starih 12 let in več, je dva vpiha v vsako nosnico enkrat dnevno.
The other two studies were carried out in children aged between two and 11 years: the first involved 558 children with perennial allergic rhinitis and the second involved 554 children with seasonal allergic rhinitis.
Preostali dve študiji sta bili opravljeni pri otrocih, starih od dve do 11 let: v prvo študijo je bilo vključenih 558 otrok s celoletnim alergijskim rinitisom, v drugo pa 554 otrok s sezonskim alergijskim rinitisom.
This is inflammation of the nasal passages caused by an allergy, resulting in runny nose, blocked nose, itching and sneezing.
To je vnetje nosne votline, ki ga povzroči alergija in ima za posledico izcedek iz nosu, zamašen nos, srbenje in kihanje.
What is the risk associated with Avamys?
Kakšna tveganja so povezana z zdravilom Avamys?
For the full list of all side effects reported with Avamys, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Avamys, glejte navodilo za uporabo.
For children between six and 12 years of age, the recommended dose is one spray in each nostril once a day, although this can be increased to two sprays if symptoms are not controlled.
Pri otrocih, starih med šest in 12 let, je priporočeni odmerek en vpih v vsako nosnico enkrat dnevno, če pa s tem odmerkom ne moremo vzpostaviti nadzora nad simptomi, ga lahko zvišamo na dva vpiha.
Avamys should not be used in people who are allergic to fluticasone furoate or any of the other ingredients.
Zdravila Avamys ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) flutikazon furoat ali katero koli drugo sestavino zdravila.
It is often accompanied by symptoms affecting the eyes, such as irritation, watering or redness.
Spremljajo ga simptomi, ki prizadenejo oči, kot je draženje, solzenje ali pordelost.
Avamys is used to treat the symptoms of allergic rhinitis.
Zdravilo Avamys se uporablja za zdravljenje simptomov alergijskega rinitisa.